Stryker Corp. is under investigation by Pomerantz LLP for potential securities fraud after the company's CEO disclosed unresolved manufacturing problems affecting inventory supply in its peripheral vascular business. This issue, initially expected to be resolved in Q3 2026, is now projected to continue into Q4, causing Stryker's stock to fall 8.81% on September 8, 2026. The investigation examines whether Stryker and its executives engaged in unlawful business practices, impacting investor trust and stock value. Investors are advised to contact Pomerantz LLP for more information or to join a class action lawsuit.
Stryker Corporation currently holds a market cap of $108.02 billion and a dividend yield of 1.25% as of October 15, 2026, 21:13 WIB. Despite the recent investigation news, the stock price on Pluang is up 2.76% at USD 289.41, with a trading volume of 2,222,698 shares. Investor interest remains strong, reflected by 100% buy orders on the platform and a typical hold time of 22 days.
Stryker Corporation reported supply disruptions in Q2 2026 that led to significant backorders and lost sales, causing its shares to fall 6.43% on July 31, 2026. The company initially expected the issue to resolve by Q3, but CFO Preston Wells later re...
The Law Offices of Frank R. Cruz is investigating Stryker Corporation for possible securities law violations after supply disruptions led to significant backorders and lost sales, causing the stock to drop sharply in July and September 2026. The comp...
Stryker has received FDA 510(k) clearance for Sonopet 3, its latest ultrasonic bone and soft tissue removal platform developed with surgeon input. The device offers enhanced power, precision, and versatility, featuring new technologies like RISE for ...
Pomerantz LLP is investigating Stryker Corp. for potential securities fraud after the company revealed ongoing manufacturing problems in its peripheral vascular business. The issue, initially expected to be resolved in Q3 2026, has persisted into Q4,...
